Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

This policy covers allogeneic hematopoietic cell transplantation for patients with primary refractory or relapsed Hodgkin's lymphoma and B- or T-cell origin non-Hodgkin's lymphoma who have no other curative-intent options, provided they are medically necessary and have a suitable pre-transplant assessment. It also affirms national CMS coverage (NCD 110.23) for allogeneic HSCT in leukemia, aplastic anemia, SCID, and Wiskott-Aldrich syndrome, and allows certain other indications (MDS, multiple myeloma with specified stages, myelofibrosis with DIPSSplus intermediate-2/high, severe symptomatic SCD) only under approved prospective clinical studies meeting CED or NCD 310.1 trial criteria.

"Allogeneic hematopoietic cell transplantation (HCT) is covered for patients with primary refractory Hodgkin's lymphoma when there are no other curative-intent treatment options and transplant is me..."